Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus lapatinib dose-comparison study in trastuzumab-pretreated HER2-positive metastatic breast cancer
2010-023237-37Phase 2Terminated
- Sponsor
- GBG Forschungs
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin and lapatinib in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Time to progression. Started Oct 2011; status: terminated.
02
Drugs
eribulinlapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-023237-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023237-37.